More recently, preclinical studies have shown that dasatinib, an ABL-class inhibitor usually given for treatment of BCR-ABL1 ALL, is surprisingly effective in a large proportion of pediatric T-ALL cases in vivo and in vitro, by which the drivers of drug sensitivity are LCK-dependent and ABL-independent [158]. The gene discussed is BCR; the disease is acute lymphoblastic leukemia.